MELBOURNE, Australia, August 28 /PRNewswire/ --

- Industry Leader Joins Atex to Drive Digital Publishing Growth, in Worlds' Greatest Developing Market

Atex is delighted to announce that Jean Paul Chauvet has joined Atex Media Command PTY, as Senior Vice President of Sales for its Asia Pacific Region, which includes Australia, New Zealand, China, India, Japan, Taiwan, Hong Kong, Vietnam, Indonesia and Malaysia.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080828/317641 )

SAO PAULO, Brazil, August 27 /PRNewswire/ --

Avon Global Ambassador, Reese Witherspoon, will travel to Sao Paulo, Brazil to celebrate the success of the company's first-ever global fundraising product, the Women's Empowerment Bracelet, which has sold 1.5 million since launching in March.

Reese will be joined by female luminaries, Nilceia Freire, Brazil's Federal Secretary for Women Policies, Ana Falu, UNIFEM Regional Director for the Southern Cone, and bio-chemist and domestic violence survivor, Maria da Penha.

SINGAPORE, August 27 /PRNewswire/ --

- Singapore's Iswaran to Highlight Asia-Pacific's Rising Energy Role at October 20 Gathering of Energy Company Executives

Singapore's top official for trade and industry, S. Iswaran, is slated to keynote the acclaimed Platts Top 250 Global Energy Companies rankings and Asia leadership recognition awards dinner and gala presentation on October 20 in Singapore.

ANTONY, France, August 27 /PRNewswire/ --

- Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber

Stallergenes S.A. announces the highly positive results of a new study conducted in an Allergen Challenge Chamber (ACC).

The study on Oralair(R) Grasses included 86 adult patients exposed to grass pollen challenge with different treatment durations: 1 week, 1 month, 2 and 4 months without a titration phase. Use of rescue medication was not allowed.

The outcomes of this trial in line with the objectives were:

COPENHAGEN, August 27 /PRNewswire/ --

- Summary: Genmab Reports Results for the Six Month Period Ended June 30, 2008

Genmab A/S (OMX: GEN) announced today results for the six month period ended June 30, 2008. During this period, Genmab reported the following results:

Genmab's revenues were DKK 277 million (USD 59 million) for the first half of 2008. In the same period of 2007, Genmab recognized revenues of DKK 280 million (USD 59 million).

ANTONY, France, August 27 /PRNewswire/ -- The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved STALLERGENES' half year consolidated financial statements:

(EUR millions) 2007 HY1 2008 HY1 08/07 % of % of % sales sales change Sales 74.8 100.0 87.0 100.0 16 Cost of sales (16.9) (22.5) (19.9) (22.8) 18 Gross profit 57.9 77.5 67.1 77.2 16 General, administrative and selling (31.3) (41.9) (35.1) (40.3) 12 expenses Gross operating profit before R&D 26.6 35.6 32.1 36.8 21 R&D (11.2) (15.0) (13.7) (15.7) 22 EBIT 15.4 20.6 18.4 13.8 19 Net profit (Group share) 10.1 13.6 12.0 13.8 19 Net borrowings 9.3 4.2 (54)

Sales growth and financial position